Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis
Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabolic dysfunction-associated steatohepatitis (MASH) compared to only 18.2% in the placebo group [difference in response: 64.8% (with a confidence interval of 51.1% - 78.6%), p<0.0001]. The study successfully achieved its main goal, as survodutide demonstrated a biopsy-verified enhancement in MASH over 48 weeks while avoiding the worsening of fibrosis stages ...
